DYN Overview

Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.

Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.

Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.

Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.

Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.

Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.

Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.

Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.

Public Offering Announcement: Dyne Therapeutics (DYN) announced an upsized underwritten public offering of 19 million shares.

Pricing Details: The pricing details of the offering were disclosed late Tuesday.